The results in the validation set confirm the performance of PON1 as a plasma biomarker to increase the diagnostic value of CRC detection, and suggest that the levels of CEA and PON1 combination could be better screened CRC than either CEA alone or combined with CA12-5 or CA19-9. This evidence concerns the gene PON1 and colorectal carcinoma.